Download PDF
Nuklearmedizin 2020; 59(01): 33-34
DOI: 10.1055/a-1044-1855
Case Report
© Georg Thieme Verlag KG Stuttgart · New York

PSMA-negative prostate cancer and the continued value of choline-PET/CT

Ian Alberts
  Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
,
Christos Sachpekidis
  Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
,
Viktor Fech
  Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
,
Axel Rominger
  Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
,
Ali Afshar-Oromieh
  Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
› Author Affiliations
Further Information

Publication History

Publication Date:
25 November 2019 (online)

    Permissions and Reprints

Short introduction

Owing to their superior uptake and higher detection rate, PSMA-labelled radioligands have largely replaced choline in routine clinical imaging of recurrent prostate cancer (PCa). Nevertheless, even at high PSA values, a small number of patients can present with PSMA negative prostate cancer (PC) lesions. For such patients choline PET continues to play an important role.

 

  • References

  • 1 Israeli RS, Powell CT, Corr JG. et al. Expression of the Prostate-specific Membrane Antigen. Cancer Res 1994; 54: 1807-1811
    Google Scholar
  • 2 Afshar-Oromieh A, Zechmann CM, Malcher A. et al. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2014; 41: 11-20 . doi:10.1007/s00259-013-2525-5
    CrossrefPubMedGoogle Scholar
  • 3 Afshar-Oromieh A, Holland-Letz T, Giesel FL. et al. Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. Eur J Nucl Med Mol Imaging 2017; 44: 1258-1268 . doi:10.1007/s00259-017-3711-7
    CrossrefPubMedGoogle Scholar
  • 4 Yakar D, Noordzij W, Kwee TC. Potential Causes of False-Negative Interpretations in 68Ga-PSMA PET/CT for the Detection of Local and Recurrent Prostate Cancer: An Underexposed Issue. Clin Nucl Med 2019; DOI: 10.1097/RLU.0000000000002750.
    CrossrefPubMedGoogle Scholar
  • 5 Noto B, Auf der Springe K, Huss S. et al. Prostate-Specific Membrane Antigen-Negative Metastases-A Potential Pitfall in Prostate-Specific Membrane Antigen PET. Clin Nucl Med 2018; 43: e186-e188 . doi:10.1097/RLU.0000000000002073
    CrossrefPubMedGoogle Scholar
  • 6 Mannweiler S, Amersdorfer P, Trajanoski S. et al. Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis. Pathol Oncol Res: POR 2009; 15: 167-172 . doi:10.1007/s12253-008-9104-2
    PubMedGoogle Scholar
  • 7 Bronsert P, Reichel K, Ruf J. Loss of PSMA Expression in Non-neuroendocrine Dedifferentiated Acinar Prostate Cancer. Clin Nucl Med 2018; 43: 526-528 . doi:10.1097/RLU.0000000000002100
    CrossrefPubMedGoogle Scholar
  • 8 Afshar-Oromieh A, Debus N, Uhrig M. et al. Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer. Eur J Nucl Med Mol Imaging 2018; 45: 2045-2054 . doi:10.1007/s00259-018-4079-z
    CrossrefPubMedGoogle Scholar